Jeffrey Cannon

1.2k total citations
55 papers, 725 citations indexed

About

Jeffrey Cannon is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Epidemiology. According to data from OpenAlex, Jeffrey Cannon has authored 55 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Public Health, Environmental and Occupational Health, 30 papers in Infectious Diseases and 17 papers in Epidemiology. Recurrent topics in Jeffrey Cannon's work include Streptococcal Infections and Treatments (43 papers), Antimicrobial Resistance in Staphylococcus (18 papers) and Infective Endocarditis Diagnosis and Management (14 papers). Jeffrey Cannon is often cited by papers focused on Streptococcal Infections and Treatments (43 papers), Antimicrobial Resistance in Staphylococcus (18 papers) and Infective Endocarditis Diagnosis and Management (14 papers). Jeffrey Cannon collaborates with scholars based in Australia, United States and United Kingdom. Jeffrey Cannon's co-authors include Jonathan R. Carapetis, Judith Katzenellenbogen, Rosemary Wyber, K Roberts, Catherine Milne, Dawn Bessarab, Joseph Hung, Laurens Manning, Rebecca Seth and Dorota A. Doherty and has published in prestigious journals such as SHILAP Revista de lepidopterología, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

Jeffrey Cannon

52 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Cannon Australia 18 497 297 261 68 63 55 725
Rachel Webb New Zealand 14 361 0.7× 290 1.0× 283 1.1× 21 0.3× 91 1.4× 57 671
Daniel J. Egan United States 11 359 0.7× 332 1.1× 98 0.4× 203 3.0× 26 0.4× 59 726
Kathleen E. Wirth United States 21 155 0.3× 317 1.1× 322 1.2× 16 0.2× 20 0.3× 53 1.1k
Jesús Almeda Spain 18 215 0.4× 261 0.9× 278 1.1× 8 0.1× 31 0.5× 75 885
M. Bruce Edmonson United States 15 135 0.3× 156 0.5× 293 1.1× 18 0.3× 23 0.4× 33 753
Alice Mitchell Australia 13 176 0.4× 85 0.3× 116 0.4× 18 0.3× 56 0.9× 25 432
Christy A. N. Okoromah Nigeria 16 140 0.3× 200 0.7× 351 1.3× 8 0.1× 68 1.1× 40 791
Salim Baharoon Saudi Arabia 14 114 0.2× 305 1.0× 161 0.6× 23 0.3× 8 0.1× 34 828
Vânia Gonçalves Portugal 15 239 0.5× 98 0.3× 147 0.6× 93 1.4× 10 0.2× 29 899

Countries citing papers authored by Jeffrey Cannon

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Cannon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Cannon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Cannon more than expected).

Fields of papers citing papers by Jeffrey Cannon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Cannon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Cannon. The network helps show where Jeffrey Cannon may publish in the future.

Co-authorship network of co-authors of Jeffrey Cannon

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Cannon. A scholar is included among the top collaborators of Jeffrey Cannon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Cannon. Jeffrey Cannon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sarna, Mohinder, Christopher C. Blyth, Belaynew Wasie Taye, et al.. (2025). Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years. The Lancet Regional Health - Western Pacific. 61. 101654–101654.
2.
Lansbury, Nina, Paul Memmott, Rosemary Wyber, et al.. (2024). Housing Initiatives to Address Strep A Infections and Reduce RHD Risks in Remote Indigenous Communities in Australia. International Journal of Environmental Research and Public Health. 21(9). 1262–1262. 1 indexed citations
3.
Lee, Jung-Seok, et al.. (2024). State transitions across the Strep A disease spectrum: scoping review and evidence gaps. BMC Infectious Diseases. 24(1). 108–108. 1 indexed citations
4.
Bowen, Asha C, Derek Roebuck, Jeffrey Cannon, et al.. (2024). Optimising detection of thrombosis in paediatric Staphylococcus aureus bacteraemia: A prospective interventional sub-study protocol. Infectious Diseases Now. 55(1). 105010–105010.
5.
Cannon, Jeffrey, et al.. (2023). Getting to grips with invasive group A streptococcal infection surveillance in Australia: are we experiencing an epidemic?. The Medical Journal of Australia. 219(6). 242–245. 3 indexed citations
6.
Cannon, Jeffrey, Julie Bennett, Anneka Anderson, et al.. (2023). Trends in penicillin dispensing during an acute rheumatic fever prevention programme. New Zealand Medical Journal. 136(1586). 84–93. 1 indexed citations
7.
Cadarette, Daniel, et al.. (2023). The full health, economic, and social benefits of prospective Strep A vaccination. npj Vaccines. 8(1). 166–166. 8 indexed citations
8.
9.
Lee, Jung-Seok, Vittal Mogasale, Jeffrey Cannon, et al.. (2023). The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts. npj Vaccines. 8(1). 128–128. 6 indexed citations
10.
Cannon, Jeffrey, Daniel Cadarette, David E. Bloom, et al.. (2023). Modeling the potential health impact of prospective Strep A vaccines. npj Vaccines. 8(1). 90–90. 10 indexed citations
11.
Cannon, Jeffrey & Rosemary Wyber. (2023). Modalities of group A streptococcal prevention and treatment and their economic justification. npj Vaccines. 8(1). 59–59. 2 indexed citations
12.
13.
Scheel, Amy, Andrea Beaton, Judith Katzenellenbogen, et al.. (2022). Standardization of Epidemiological Surveillance of Rheumatic Heart Disease. Open Forum Infectious Diseases. 9(Supplement_1). S50–S56. 2 indexed citations
14.
Scheel, Amy, Andrea Beaton, Judith Katzenellenbogen, et al.. (2022). Standardization of Epidemiological Surveillance of Acute Rheumatic Fever. Open Forum Infectious Diseases. 9(Supplement_1). S41–S49. 2 indexed citations
15.
Carapetis, Jonathan R., Thomas Cherian, Roderick J. Hay, et al.. (2022). Standardization of Epidemiological Surveillance of Group A Streptococcal Impetigo. Open Forum Infectious Diseases. 9(Supplement_1). S15–S24. 1 indexed citations
16.
Bond‐Smith, Daniela, Karen Dempsey, Jeffrey Cannon, et al.. (2019). The End Rheumatic Heart Disease in Australia Study of Epidemiology (ERASE) Project: data sources, case ascertainment and cohort profile. SHILAP Revista de lepidopterología.
17.
Katzenellenbogen, Judith, Daniela Bond‐Smith, Rebecca Seth, et al.. (2019). <p>The End Rheumatic Heart Disease in Australia Study of Epidemiology (ERASE) Project: data sources, case ascertainment and cohort profile</p>. Clinical Epidemiology. Volume 11. 997–1010. 32 indexed citations
18.
Barnett, Timothy C., Jeffrey Cannon, Jonathan R. Carapetis, et al.. (2019). SToP (See, Treat, Prevent) skin sores and scabies trial: study protocol for a cluster randomised, stepped-wedge trial for skin disease control in remote Western Australia. BMJ Open. 9(9). e030635–e030635. 17 indexed citations
19.
Cannon, Jeffrey, et al.. (2018). Severe lower limb cellulitis: defining the epidemiology and risk factors for primary episodes in a population-based case-control study. Clinical Microbiology and Infection. 24(10). 1089–1094. 21 indexed citations
20.
Cannon, Jeffrey, John R. Dyer, Jonathan R. Carapetis, & Laurens Manning. (2018). Epidemiology and risk factors for recurrent severe lower limb cellulitis: a longitudinal cohort study. Clinical Microbiology and Infection. 24(10). 1084–1088. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Webb Breakdown of academic impact, for papers by Daniel J. Egan Breakdown of academic impact, for papers by Kathleen E. Wirth Breakdown of academic impact, for papers by Jesús Almeda Breakdown of academic impact, for papers by M. Bruce Edmonson Breakdown of academic impact, for papers by Alice Mitchell Breakdown of academic impact, for papers by Christy A. N. Okoromah Breakdown of academic impact, for papers by Salim Baharoon Breakdown of academic impact, for papers by Vânia Gonçalves
Rankless by CCL
2026